HK1169648A1 - 新型乙酰水楊酸鹽 - Google Patents

新型乙酰水楊酸鹽

Info

Publication number
HK1169648A1
HK1169648A1 HK12110406.3A HK12110406A HK1169648A1 HK 1169648 A1 HK1169648 A1 HK 1169648A1 HK 12110406 A HK12110406 A HK 12110406A HK 1169648 A1 HK1169648 A1 HK 1169648A1
Authority
HK
Hong Kong
Prior art keywords
acid salts
acetylsalicylic acid
novel
novel acetylsalicylic
salts
Prior art date
Application number
HK12110406.3A
Other languages
English (en)
Inventor
Ivars Kalvins
Anatolijs Birmans
Maris Veveris
Antons Lebedevs
Anatolijs Misnovs
Original Assignee
Sia Tetra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from LVP-09-117A external-priority patent/LV14273B/lv
Priority claimed from LVP-10-95A external-priority patent/LV14468B/lv
Application filed by Sia Tetra filed Critical Sia Tetra
Publication of HK1169648A1 publication Critical patent/HK1169648A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/14—Acetic acid esters of monohydroxylic compounds
    • C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
    • C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/40—Hydrazines having nitrogen atoms of hydrazine groups being quaternised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK12110406.3A 2009-06-25 2012-10-19 新型乙酰水楊酸鹽 HK1169648A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LVP-09-117A LV14273B (lv) 2009-06-25 2009-06-25 Jauni acetilsalicilskābes sāļi
LVP-10-95A LV14468B (lv) 2010-06-21 2010-06-21 Pretiekaisuma līdzeklis
PCT/LV2010/000007 WO2010151095A1 (en) 2009-06-25 2010-06-21 Novel acetylsalicylic acid salts

Publications (1)

Publication Number Publication Date
HK1169648A1 true HK1169648A1 (zh) 2013-02-01

Family

ID=42562394

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12110406.3A HK1169648A1 (zh) 2009-06-25 2012-10-19 新型乙酰水楊酸鹽

Country Status (13)

Country Link
US (1) US8889902B2 (zh)
EP (1) EP2445861B1 (zh)
JP (1) JP5706409B2 (zh)
KR (1) KR20120050437A (zh)
CN (1) CN102803199B (zh)
BR (1) BRPI1009600A2 (zh)
CA (1) CA2766048A1 (zh)
EA (1) EA021588B1 (zh)
GE (1) GEP20146015B (zh)
HK (1) HK1169648A1 (zh)
IL (1) IL217036A (zh)
NZ (1) NZ597510A (zh)
WO (1) WO2010151095A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012146737A1 (en) * 2011-04-27 2012-11-01 Grindeks, A Joint Stock Company 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease
RS55092B1 (sr) * 2011-04-27 2016-12-30 Grindeks Jsc Upotreba 3-karboksi-n-etil-n,n-dimetilpropan-1-aminijum soli u lečenju kardiovaskularne bolesti
LV14606B (lv) 2011-05-17 2013-01-20 Tetra, Sia Jauns XII faktora inhibitors
RU2457202C1 (ru) * 2011-05-31 2012-07-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний)пропионата - 5- гидрокисиникотинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее противоишемической активностью
RU2458054C1 (ru) * 2011-05-31 2012-08-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний) пропионата - никотинат 3-(2,2,2-триметилгидразиний) пропионат калия, обладающее противоишемической активностью
RU2465268C1 (ru) * 2011-08-08 2012-10-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний)пропионата - никотинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее эндотелиопротекторной активностью
LV14848B (lv) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija trimetilamīna-N-oksīda līmeņa pazemināšanai
JO3117B1 (ar) * 2012-12-20 2017-09-20 Grindeks Jsc استعمال 3- كربوكسي- ن-إيثيل- ن، ن- ثاني ميثيل بروبان-1– أمينيوم أو ملح منه مقبول صيدلانياً في معالجة تصلب الشرايين
LV14963B (lv) 2013-06-28 2015-10-20 Tetra, Sia Endoteliālās disfunkcijas korektors
GB201413355D0 (en) * 2014-07-28 2014-09-10 Innospec Ltd Compositons and methods
CN104997754A (zh) * 2015-08-05 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种解热镇痛药阿司匹林组合物胶囊
CN105106134A (zh) * 2015-09-23 2015-12-02 青岛华之草医药科技有限公司 一种解热镇痛抗炎药阿司匹林组合物颗粒剂
CN106008257A (zh) * 2016-03-16 2016-10-12 江苏悦兴药业有限公司 米屈肼的制备方法及其关键中间体
CN110996965A (zh) 2017-05-30 2020-04-10 罗山制药股份有限公司 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物
RU2694835C1 (ru) * 2018-12-07 2019-07-17 Федеральное государственное автономное образовательное учреждение высшего образования "Северный (Арктический) федеральный университет имени М.В. Ломоносова" Средство, повышающее резистентность организма в постгипотермическом периоде
KR20220126254A (ko) * 2021-03-08 2022-09-15 주식회사 엘지생활건강 카르니틴살리실레이트(ca-sa)를 유효성분으로 포함하는 화장료 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3312593A (en) 1965-03-10 1967-04-04 Carter Prod Inc Anti-inflammatory compositions of aspirin and niacin
JPS5610110A (en) * 1979-07-06 1981-02-02 Green Cross Corp:The Acetyl salicylate salt preparation for injection
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US4625888A (en) 1985-11-18 1986-12-02 Thompson Andy L Ground actuated lid operating system
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
CH679856A5 (zh) * 1990-07-04 1992-04-30 Lonza Ag
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
CA2218696A1 (en) 1995-04-19 1996-10-24 L. Jackson Ii Roberts Compositions, kits and methods for administration of antilipemic and an ti-platelet aggregation drugs
FR2744918B1 (fr) 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FR2751540B1 (fr) 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US6469035B1 (en) 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
DE19839443A1 (de) * 1998-08-29 2000-03-02 Miklos Ghyczy Arnzneimittel mit entzündungshemmender Wirkung
DE10034802A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
DE10202019A1 (de) * 2002-01-18 2003-07-24 Bayer Ag Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II
DK1667960T3 (da) * 2003-08-04 2008-06-09 Grindeks Jsc Meldoniumsalte, fremgangsmåde til deres fremstilling og farmaceutisk sammensætning på deres basis
US20060205727A1 (en) 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
DE102005025283A1 (de) * 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
LV13544B (en) * 2005-08-15 2007-05-20 Grindeks As Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium
ITMI20052459A1 (it) * 2005-12-22 2007-06-23 Isagro Spa Sali quaternari e relativo uso per il controllo di fitopatogeni
EP2303327A2 (en) 2008-05-20 2011-04-06 Cerenis Therapeutics S.A. Niacin and nsaid for combination therapy

Also Published As

Publication number Publication date
CA2766048A1 (en) 2010-12-29
EA021588B1 (ru) 2015-07-30
BRPI1009600A2 (zh) 2016-03-22
CN102803199A (zh) 2012-11-28
WO2010151095A1 (en) 2010-12-29
WO2010151095A8 (en) 2012-05-18
GEP20146015B (en) 2014-01-27
EA201200038A1 (ru) 2012-10-30
EP2445861A1 (en) 2012-05-02
US20120088742A1 (en) 2012-04-12
CN102803199B (zh) 2015-04-15
JP2012531408A (ja) 2012-12-10
US8889902B2 (en) 2014-11-18
NZ597510A (en) 2012-12-21
JP5706409B2 (ja) 2015-04-22
KR20120050437A (ko) 2012-05-18
EP2445861B1 (en) 2014-03-26
IL217036A0 (en) 2012-02-29
IL217036A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
HK1169648A1 (zh) 新型乙酰水楊酸鹽
HRP20190509T1 (hr) Spoj piridilaminooctene kiseline
IL215691A0 (en) Carboxylic acid compound
BRPI1009192A2 (pt) preparação de ácido adípico
ME02254B (me) Derivati hidroksamske kiseline
EP2527400A4 (en) polylactic acid
SI2421808T1 (sl) Analogi 4-hidroksi maslene kisline
GB0908772D0 (en) New salts 756
EP2583994A4 (en) polylactic acid
EP2490618A4 (en) TISSUE-SEALING FATTYLENE-LIGHTING BARRIER
ZA201108850B (en) Solid compositions comprising 5-aminolevulinic acid
HK1226051A1 (zh) 14-羥基-二十二烯酸化合物
ZA201306560B (en) Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
EP2637660A4 (en) GRAS SYNTHASE ACID INHIBITORS
IL206524A0 (en) 4-dimethylminobutyric acid derivatives
GB0904101D0 (en) Percusion mole
EP2567675A4 (en) BONE TRANSPLANTATION OR BONE FILLING COMPOSITION WITH A DIHYDROXYBENZOIC ACID DERIVATIVE
EP2542232A4 (en) FATTY ACID INHIBITORS
EP2451976A4 (en) NANO-BIOSENSORS WITH NUCLEIC ACIDS
EP2355796A4 (en) salicylic acid composition
EP2262758A4 (en) O-desmethylvenlafaxine SALTS
PL2187863T3 (pl) Przeciwpotowe sole okso-heksameryczny cyrkon-oktaaminokwasu
GB0904300D0 (en) Essential fatty acid compounds
EP2381524A4 (en) LEAD BATTERY
HK1193407A1 (zh) 吡咯烷- -基乙酸衍生物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180621